Toward predictors of survival in castration-resistant prostate cancer

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

Original languageEnglish (US)
Pages (from-to)3882-3884
Number of pages3
JournalCancer
Volume117
Issue number17
DOIs
StatePublished - Sep 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this